Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

2.
3.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

4.

Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.

Ollendorf DA, Peterson AN, Doyle J, Huse DM.

Am J Manag Care. 2002 May;8(7 Suppl):S203-13.

5.

The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.

Benucci M, Li Gobbi F, Sabadini L, Saviola G, Baiardi P, Manfredi M.

Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1147-52.

PMID:
20074482
7.

Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.

Davies A, Cifaldi MA, Segurado OG, Weisman MH.

J Rheumatol. 2009 Jan;36(1):16-26. doi: 10.3899/jrheum.080257.

PMID:
19012363
8.

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M.

Pharmacoeconomics. 2001;19(10):1051-64.

PMID:
11735673
9.

Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France.

Fautrel B, Woronoff-Lemsi MC, Ethgen M, Fein E, Monnet P, Sibilia J, Wendling D.

Joint Bone Spine. 2005 Dec;72(6):550-6.

PMID:
15996504
10.

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Pharmacoeconomics. 2005;23(4):377-93.

PMID:
15853437
11.
12.

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.

Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, Geborek P, Neovius M.

Ann Rheum Dis. 2015 Jun;74(6):1094-101. doi: 10.1136/annrheumdis-2013-205060. Epub 2014 Apr 15.

14.

Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.

Korthals-de Bos I, Van Tulder M, Boers M, Verhoeven AC, Adèr HJ, Bibo J, Boonen A, Van Der Linden S.

J Rheumatol. 2004 Sep;31(9):1709-16.

PMID:
15338488
16.

Advances in the medical management of rheumatoid arthritis.

Scott DL.

Hosp Med. 2002 May;63(5):294-7. Review.

PMID:
12066349
17.

[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Z Rheumatol. 2004 Feb;63(1):59-75. German.

PMID:
14991279
18.

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.

Griffiths RI, Bar-Din M, MacLean CH, Sullivan EM, Herbert RJ, Yelin EH.

Arthritis Care Res. 2000 Aug;13(4):213-26.

19.
20.

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.

Bansback NJ, Brennan A, Ghatnekar O.

Ann Rheum Dis. 2005 Jul;64(7):995-1002. Epub 2004 Nov 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk